Your session is about to expire
← Back to Search
Onalespib + CDKI AT7519 for Advanced Cancer
Study Summary
This trial is testing onalespib and CDKI AT7519 to see what effects (good and bad) they have on patients with solid tumors that have spread or cannot be removed by surgery.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have brain metastases or carcinomatous meningitis but meet certain conditions.My cancer can be measured or evaluated using specific criteria.My kidney function is within the normal range.I have recovered from previous cancer treatment side effects, except for hair loss.I have not had chemotherapy or radiotherapy recently.I am not pregnant, don't have HIV, heart issues, severe nerve damage, or serious eye disease.My liver tests are within the normal range.I am fully active or can carry out light work.My cancer has spread, cannot be surgically removed, and standard treatments are not effective.
- Group 1: Treatment (onalespib, CDKI AT7519)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Have any other pharmacological studies been conducted prior to this one?
"Currently, 4 clinical trials are underway to learn more about Pharmacological Study. All of these studies remain in the pre-Phase 3 stages and a total of 18 sites from Toronto, Ontario have been selected for the trial."
Is this clinical investigation still open to enrolment?
"Unfortunately, this research endeavour is not currently accepting patients. Initially posted on April 8th 2016 and modified lastly on October 18th 2022, there are presently 2397 cancer studies actively recruiting as well as 4 Pharmacological Studies with open enrollment."
What is the current size of the population being treated through this trial?
"Unfortunately, this trial is not currently seeking participants. The posting went live on April 8th 2016 and was last updated October 18th 2022. Patients searching for active medical studies may be interested in the 2397 cancer trials or 4 pharmacological studies that are open to patients at present."
What health risks might participants in a Pharmacological Study face?
"Due to the preliminary nature of this pharmacological study, it received a score of 1. This indicates that there is limited evidence supporting its safety and efficacy."
In which areas are the administrators of this clinical trial overseeing operations?
"There are 6 recruitment centres for the trial, including Massachusetts General Hospital Cancer Centre in Boston, Dana-Farber Cancer Institute in Columbus and Ohio State University Comprehensive Cancer Center in Washington."
Share this study with friends
Copy Link
Messenger